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AbstrAct
Development of malignancy is accompanied by a complete metabolic 
reprogramming closely related to the acquisition of most of cancer hallmarks. In 
fact, key oncogenic pathways converge to adapt the metabolism of carbohydrates, 
proteins, lipids and nucleic acids to the dynamic tumor microenvironment, conferring 
a selective advantage to cancer cells. Therefore, metabolic properties of tumor 
cells are significantly different from those of non-transformed cells. In addition, 
tumor metabolic reprogramming is linked to drug resistance in cancer treatment. 
Accordingly, metabolic adaptations are specific vulnerabilities that can be used in 
different therapeutic approaches for cancer therapy. In this review, we discuss 
the dysregulation of the main metabolic pathways that enable cell transformation 
and its association with oncogenic signaling pathways, focusing on the effects of 
c-MYC, hypoxia inducible factor 1 (HIF1), phosphoinositide-3-kinase (PI3K), and the 
mechanistic target of rapamycin (mTOR) on cancer cell metabolism. Elucidating these 
connections is of crucial importance to identify new targets and develop selective 
cancer treatments that improve response to therapy and overcome the emerging 
resistance to chemotherapeutics.
IntroductIon
Multifactorial diseases are the final result of 
the interaction between genetic susceptibility and 
environmental factors in which a clear hereditary pattern 
is not found. This complexity causes difficulties in the 
risk evaluation, diagnosis and treatment of these diseases. 
Cancer, one of the most prevalent multifactorial diseases, 
is characterized by the lost of physiological control and the 
malignant transformation of cells that acquire functional 
and genetic abnormalities, leading to tumor development 
and progression. In some cases, cancer cells have the 
ability to invade other tissues resulting in metastasis, the 
major cause of death from cancer. According to the most 
recent data released by the World Health Organization 
(WHO) in 2012, more than 14 million of new cancer 
cases were diagnosed, and 8.2 million cancer deaths and 
32.4 million people living with cancer (within 5 years 
of diagnosis) were registered worldwide [1]. The most 
common cancers by primary site location were lung, 
prostate and colorectal in men, and breast, colorectal and 
cervix uteri in women [1].
Tumor cells present common biological capabilities 
sequentially acquired during the development of cancer 
that are considered essential to drive malignancy and 
known as the hallmarks of cancer [2]. These hallmark 
capabilities include sustaining proliferative signaling, 
evading growth suppressors, avoiding immune destruction, 
enabling replicative immortality, activating invasion and 
metastasis, inducing angiogenesis, resisting cell death and 
reprogramming cellular metabolism. In addition, there 
are two consequential characteristics of tumorigenesis 
that enable the acquisition of the hallmarks of cancer. The 
most prominent is the development of genomic instability 
and mutability, which endow tumor cells with genetic 
alterations that can orchestrate tumor progression. The 
second one involves the tumor-promoting inflammation 
by innate immune cells, which in turn serve to support 
multiple hallmark capabilities [2].
Non-transformed cells tightly regulate the 
mitogenic signaling that command cell growth and 
division in order to maintain a balance between cell 
proliferation and death. Accordingly, the dysregulation 
of the signaling pathways that regulate the progression 
through cell cycle, cell survival and metabolism may 
lead to malignant transformation. It is worth noting 
that neoplastic transformation requires not only the 
alteration of proliferative stimuli but also the disruption 
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of mechanisms that prevent unrestrained proliferation 
such as programmed cell death (apoptosis) or negative-
feedback signaling [3]. Likewise, the cooperative 
activation of oncogenes (genes that promote cell growth, 
proliferation and survival) and/or inactivation of tumor 
suppressor genes (genes that restrain cell growth and 
proliferation, promote DNA repair or trigger apoptosis) 
are involved in tumor development [3, 4]. Oncogenes 
can be activated through several mechanisms including 
upregulated transcriptional expression, increased stability 
of mutant proteins, altered functionality of proteins and 
abnormal recruitment or subcellular localization of gene 
products through interaction with aberrantly expressed or 
mutant binding partners [3, 5]. The products of oncogenes 
comprise transcription factors (e.g. c-MYC, hereafter 
referred to as MYC), growth factor receptors (e.g. EGFR), 
signal transduction proteins (e.g. RAS and PI3K), serine-
threonine protein kinases (e.g. Akt, mTOR, CDK4 and 
CDK6) and inhibitors of apoptosis (e.g. BCL2) [5]. On 
the other hand, tumor suppressor genes encode proteins 
that inhibit cell division and cell proliferation (e.g. RB, 
p53, p16INK4a, PTEN), stimulate cell death (e.g. caspase 8 
and p53) and repair damaged DNA (e.g. MSH2, MSH6, 
ATM and ATR) [6].
Accumulation of genetic alterations is associated 
with tumor evolution, which includes single nucleotide 
mutations and also whole-chromosomal changes [7-9]. 
In addition, epigenetic mechanisms including histone 
modifications, DNA methylation and non-coding 
RNAs are involved in carcinogenesis [10, 11]. In fact, 
tumors often display aberrant methylation patterns 
such as hypermethylation on the promoters of tumor 
suppressor genes causing transcriptional repression, and 
hypomethylation of oncogenes supporting their activation 
(reviewed in [11, 12]). Epigenetic modifications have been 
reported to regulate the Warburg effect and coordinate 
the overall cellular metabolism, including the pentose 
phosphate pathway and other pathways for sugar, lipid 
and amino acid metabolism, by affecting several metabolic 
enzyme activities [13-16]. Remarkably, oxidative stress is 
involved with both genetic and epigenetic modifications, 
playing an important role in carcinogenesis [10, 17].
MetAbolIc reprogrAMMIng of 
tuMor cells
Metabolism is the term that is used to describe 
the integrated network of chemical reactions involved 
in sustaining growth, proliferation and survival of cells 
and organisms. These reactions are catalyzed by tightly 
regulated enzymes, which sense environmental cues and 
provide energy, reducing power and macromolecules to 
supply the cellular needs. Metabolic reactions can be 
classified into catabolic pathways that produce energy 
(adenosine triphosphate, ATP) through the breakdown 
of molecules, and anabolic pathways that synthesize 
molecules through energy-consuming processes. The 
metabolic network is regulated by signaling pathways that 
respond to the specific cellular needs which, in turn, may 
vary depending on the cell type and proliferative state.
Despite the fact that there are several metabolic 
similarities between tumor and highly proliferating non-
transformed cells (reviewed in [18]), oncogenic regulation 
and tumor microenvironment have a distinctive influence 
on the metabolic reprogramming of cancer cells. In 
particular, tumor cells switch their core metabolism 
to meet the increased requirements of cell growth and 
division. Indeed, tumor metabolic reprogramming 
involves the enhancement of key metabolic pathways such 
as glycolysis, pentose phosphate pathway, glutaminolysis 
and lipid, nucleic acid and amino acid metabolism [19] 
(Figure 1). Thus, activation of oncogenic signaling 
pathways adapts tumor cells metabolism to the dynamic 
tumor microenvironment, where nutrient and oxygen 
concentrations are spatially and temporally heterogeneous 
[20, 21]. The dependencies on specific metabolic 
substrates such as glucose or glutamine exhibited by 
tumor cells are determined by the alterations in their 
oncogenes and tumor suppressor genes. For instance, 
MYC-transformed cells display addiction to glutamine 
as a bioenergetic substrate and are sensitive to inhibitors 
of glutaminolysis [22]. Accordingly, the characterization 
of the metabolic reprogramming of cancer cells and its 
connection with oncogenic signaling is a promising 
approach to identify novel molecular-targeted strategies 
in cancer therapy. 
glycolysis and the Warburg effect
Glycolysis is the metabolic pathway by which 
glucose and other sugars are metabolized to pyruvate 
in an oxygen-independent manner to generate energy in 
the form of ATP and intermediates, which are used as 
precursors for the biosynthesis of macromolecules [23]. 
Under physiologic oxygen concentrations, pyruvate enters 
the mitochondria to be oxidized through an oxygen-
dependent process known as oxidative phosphorylation 
(OXPHOS), which couples the oxidation of metabolites 
and the electron transport chain (ETC) with ATP 
production, being also a potential source of reactive 
oxygen species (ROS) [20].
The first metabolic phenotype observed in tumor 
cells was described by Otto Warburg as a shift from 
oxidative phosphorylation to aerobic glycolysis to 
generate lactate and ATP even in presence of oxygen, 
which is known as the Warburg effect [24, 25]. Therefore, 
cancer cells convert most incoming glucose to lactate 
rather than entering in the mitochondria to be oxidized 
through oxidative phosphorylation [26]. Initially, it was 
believed that the Warburg effect resulted from defects 
in the mitochondrial function of cancer cells. However, 
this effect is also exhibited by tumor cells with intact and 
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functional mitochondria, suggesting that their preference 
for glycolysis might confer benefits on them such as 
reduced levels of ROS, high production of metabolic 
intermediates for macromolecular biosynthesis and 
acidification of extracellular microenvironment due to 
lactate excretion [27, 28]. It is worth noting that the ATP 
produced per molecule of glucose catabolized through 
glycolysis is considerably less efficient than through 
oxidative phosphorylation (2 versus 31-38 molecules of 
ATP [29], respectively), causing tumor cells to greatly 
increase both the rate of glucose uptake and glycolysis 
to sustain their increased energetic, biosynthetic and 
redox needs [30]. Conveniently, the high glycolytic rates 
displayed by cancer cells allow their visualization by 
18F-deoxyglucose positron emission tomography (FDG-
PET) and assist tumor detection, prevention and treatment 
[31].
Over the past decade, numerous studies and reviews 
have supported the hypothesis that the Warburg effect 
can be explained by the alterations in multiple signaling 
pathways resulting from mutations in oncogenes and tumor 
suppressor genes [21, 28, 32-35]. The complex network of 
mechanisms leading to the Warburg phenomenon includes 
mitochondrial changes, upregulation of rate-limiting 
enzymes in glycolysis involving specific isoforms such 
as M2 pyruvate kinase and hexokinase 2, intracellular 
pH regulation, and hypoxia-induced switch to anaerobic 
metabolism (reviewed in [35]). The enhanced glycolytic 
figure 1: Major metabolic pathways involved in tumor metabolic reprogramming. An overview of the main catabolic 
and anabolic metabolic pathways supporting tumor cell growth and survival. Enzymes are shown in bold. 6PGD, 6-phosphogluconate 
dehydrogenase; ACLY, ATP citrate lyase; CoA, coenzyme A; GLS, glutaminase; GDH, glutamate dehydrogenase; G6PD, glucose-6-
phosphate dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LDH, lactate dehydrogenase; ME1, malic enzyme 
1 cytoplasmic form; ME2, malic enzyme 2 mitochondrial form; NAD+, nicotinamide adenine dinucleotide oxidized form; NADH, 
nicotinamide adenine dinucleotide reduced form; NADPH, nicotinamide adenine dinucleotide phosphate reduced form; PC, pyruvate 
carboxylase; PDH, pyruvate dehydrogenase; PGM, phosphoglucomutase. 
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rate can be sustained through the overexpression of 
glucose transporters [36] and several key glycolytic 
enzymes [37] mediated by specific activated oncogenes 
(e.g. PI3K and MYC) and transcription factors (e.g. HIF1), 
contributing to the acquisition of the Warburg effect and 
maintaining tumor cell growth and survival [21, 28, 33]. 
Likewise, loss-of-function mutations in tumor suppressor 
TP53 (encoding p53) also contribute to the Warburg 
effect, since they prevent i) p53-mediated transcriptional 
repression of glucose transporters GLUT1 and GLUT4; 
ii) activation of cytochrome c oxidase assembly protein 
(SCO2) expression, which promotes OXPHOS; and iii) 
upregulation of TP53-induced glycolysis and apoptosis 
regulator (TIGAR) expression, which reduces the 
intracellular concentration of the glycolytic activator 
fructose-2,6-bisphosphate [20, 38].
Interestingly, the metabolic switch in tumor cells 
has a key role in the establishment of many other cancer 
hallmarks [19]. In fact, some metabolic enzymes have 
been described as multifaceted proteins which can directly 
regulate transcription, glucose homeostasis and resistance 
to cell death [39, 40]. For example, hexokinase 2 isoform 
(HK2), which catalyzes the rate-limiting first step of 
glycolysis, plays a key role for the Warburg effect in 
cancer [41-43]. Specifically, HK2 bounds to mitochondria 
and is recognized as a signaling component controlling 
cellular growth, preventing mitochondrial apoptosis and 
enhancing autophagy [44, 45]. The competitive binding 
of HK2 to the voltage-dependent anion channel (VDAC) 
in the outer mitochondrial membrane prevents the union 
of VDAC with pro-apoptotic Bax, inhibiting cytochrome 
c release from mitochondria and avoiding apoptosis after 
Bax activation [44]. Therefore, targeting multifunctional 
metabolic enzymes may restore the susceptibility of tumor 
cells to cell death, offering new options for cancer therapy. 
pentose phosphate pathway
Pentose phosphate pathway (PPP) is one of the main 
metabolic pathways that enables tumor cell proliferation 
by regulating the flux of carbons between nucleic acid 
synthesis and lipogenesis to support DNA replication 
and RNA production. DNA and RNA nucleic acids are 
polymers composed by combinations of four different 
nucleotides which in turn are constituted by an organic 
base (purine, in the case of the nucleotides adenine 
and guanine, or pyrimidine, in the case of cytosine, 
thymine, and uracil), a pentose sugar (ribose for RNA or 
deoxyribose for DNA) and one or more phosphate groups. 
The pentose phosphate is mainly obtained through the PPP, 
which also generates nicotinamide adenine dinucleotide 
phosphate (NADPH). NADPH is an essential cofactor for 
providing reducing equivalents for lipid and amino acid 
biosynthesis, and for modulating oxidative stress through 
the maintenance of the reduced glutathione (GSH) pool 
[46]. The association between upregulation of PPP and 
tumor cell proliferation is been extensively studied, as PPP 
plays a pivotal role in allowing tumor cells to meet their 
anabolic demands and counteract oxidative stress [47-49].
PPP is divided into the oxidative branch and the 
non-oxidative branch. The oxidative branch catalyzes 
the irreversible transformation of glucose-6-phosphate 
into ribose-5-phosphate (R5P), yielding NADPH. 
The non-oxidative branch is a reversible pathway that 
interconverts R5P and glycolytic intermediaries. The 
enzymes that mainly regulate the PPP are glucose-6-
phosphate dehydrogenase (G6PD) in the oxidative branch 
and transketolase (TKT) in the non-oxidative branch [50-
52]. Several oncogenic signaling pathways promote G6PD 
activation by post-translational mechanisms [46], while 
tumor suppressor p53 directly inhibits G6PD and the PPP 
[48]. PPP is coordinated with cell cycle since proliferating 
cells increase G6PD activity during late G1 and S phases 
[53]. Moreover, the activation of the SCF ubiquitin ligase 
by its interaction with the protein-b-transduction repeat-
containing protein (b-TrCP) allows the recognition of 
PFKFB3 and its proteasome degradation during S phase 
[54, 55], promoting the shuttling of glycolytic substrates 
through the PPP and increasing the production of NADPH 
and R5P to allow S phase progression. 
lipid metabolism
Triacylglycerides, phosphoglycerides, sterols and 
sphingolipids are hydrophobic or amphipathic molecules 
known as lipids. Fatty acids are long hydrocarbon chains 
with a carboxy-terminal group that constitute the main 
component of triacylglycerides and phosphoglycerides, 
being also present in sphingolipids and sterol esters. 
While triacylglycerides are used as energy storage units, 
phosphoglycerides, sterols and sphingolipids are major 
structural components of plasma membranes. Lipids are 
also involved in signal transduction and participate in the 
regulation of cell growth, proliferation, differentiation, 
survival, apoptosis, membrane homeostasis, motility and 
drug resistance [56, 57]. 
Tumor metabolic reprogramming involves an 
increase in lipid biosynthesis to supply the building 
blocks for membrane formation and sustain the high 
proliferative rate of tumor cells. Distinctively, tumor cells 
mainly activate and thrive on de novo lipid biosynthesis, 
while most non-transformed cells rely on extracellular 
lipids. Oncogenic signaling enhances lipogenesis through 
the increase of precursors for fatty acids synthesis (i.e. 
promoting glucose and glutamine transport, glycolysis, 
PPP and anaplerosis) and the upregulation of many 
lipogenic enzymes such as ATP citrate lyase (ACLY), fatty 
acid synthase (FASN) and acetyl-CoA carboxylase (ACC) 
[58-61]. The acetyl groups for fatty acids biosynthesis are 
provided by mitochondrial citrate, which is exported to the 
cytosol where ACLY catalyzes its conversion into acetyl-
CoA and oxaloacetate [62]. Then, malate dehydrogenase 
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(MDH) and malic enzyme (ME) can produce pyruvate 
from oxaloacetate, yielding part of the NADPH required 
for fatty acid biosynthesis. In addition, lipid biosynthesis 
is also connected to other pathways that generate NADPH, 
such as the oxidative branch of the PPP. Next, acetyl-CoA 
is converted to malonyl-CoA by ACC, and both acetyl and 
malonyl groups are condensed through a cyclical series 
of reactions by FASN, resulting in long-chain saturated 
fatty acids, predominantly palmitate. Further elongation 
and desaturation of de novo synthesized saturated fatty 
acids can be obtained through the action of elongases and 
desaturases [56, 63]. On the other hand, the mitochondrial 
degradation of fatty acids through β-oxidation releases 
large amounts of ATP and generates ROS through the TCA 
cycle and the oxidative phosphorylation [56, 57].
Sterol regulatory element-binding proteins 
(SREBPs) transcription factors regulate the expression 
of most enzymes involved in the synthesis of fatty acids 
and cholesterol. In turn, SREBPs are negatively regulated 
by tumor suppressors such as p53, pRB and AMPK, 
and activated by oncogenes such as PI3K and Akt. For 
instance, besides promoting glycolysis, Akt upregulates 
the expression of the lipogenic enzymes through activation 
and nuclear translocation of SREBP [64], and positively 
regulates ACLY by direct phosphorylation [65], linking 
enhanced glycolysis with increased lipogenesis [63, 66]. 
Therefore, targeting lipogenic pathways is thought to 
be a promising strategy for cancer therapy, as lipogenic 
enzymes are found to be upregulated or activated in tumor 
cells to satisfy their increased demand for lipids [57, 58].
Amino acid metabolism
Amino acids are organic compounds containing a 
specific side chain and both amino and carboxyl groups 
that enable them to undergo polymerization to form 
proteins. In addition, amino acids can be metabolized 
as a source of carbon and nitrogen for biosynthesis. 
There are 20 different amino acids, 11 of which can be 
endogenously synthesized by mammal cells while the 
remainder are known as essential amino acids, which must 
be obtained from external sources. In fact, amino acids 
have a pivotal role in supporting proliferative metabolism 
and are required for cell survival. It is not surprising 
that cells have developed an amino acid sensing system 
through the mechanistic target of rapamycin (mTOR) 
signaling to determine whether there are sufficient amino 
acids available for protein biosynthesis. Specifically, 
leucine, glutamine and arginine serve as critical signaling 
molecules that activate mTOR pathway [67, 68]. In 
response to amino acid deficiency, inhibition of mTOR 
rapidly suppress protein synthesis and induce autophagy, 
in order to maintain a free amino acid pool which may be 
required during prolonged amino acid limitation [69].
Non-essential aminoacids can be synthesized from 
glycolytic intermediates such as 3-phosphoglycerate, 
which is the precursor for serine, or pyruvate, that can be 
converted to alanine. In addition, TCA intermediates like 
oxaloacetate and α-ketoglutarate can generate aspartate, 
asparagine and glutamate. Moreover, glutamate can 
be converted to L-glutamate-5-semialdehyde (GSA) 
and 1-pyrroline-5-carboxylate (P5C), which are further 
converted to ornithine and proline, respectively [70]. 
Then, ornithine can enter the urea cycle and produce 
arginine. Also, serine can generate glycine and contribute 
to the synthesis of cysteine [71]. 
Highly proliferating cells, like tumor cells, consume 
essential and non-essential amino acids from external 
sources since the capacity of endogenous synthesis is not 
sufficient to fulfill their amino acidic increased needs [72]. 
However, most amino acids are hydrophilic molecules 
that require selective transport proteins to cross the cell 
membrane. Accordingly, four amino acid transporters 
(SLC1A5 [22, 73], SLC7A5 [73], SLC7A11 [74] and 
SLC6A14 [75]) have been found to be overexpressed 
in cancer cells in a MYC-dependent manner or through 
miR-23a repression mediated by MYC to increase the 
uptake of amino acids and meet their growing demands 
[72]. Interestingly, the functional coupling of SLC1A5 and 
SLC7A5 glutamine transporters suggests that enhanced 
glutamine metabolism in tumor cells can contribute to 
drive tumor growth through activation of mTOR [68].
In tumor cells, the consumption of some amino 
acids (specially non-essential amino acids) greatly 
exceeds the requirements for protein biosynthesis, 
suggesting their use as intermediates in metabolism 
by providing one carbon units, replenishing the TCA 
cycle or synthesizing fatty acids, nucleotides and other 
amino acids [71]. For example, glutamine, glycine and 
aspartate are required for nucleotide biosynthesis, while 
serine and glycine play an essential role in a one-carbon 
metabolism, generating precursors for the biosynthesis 
of lipids, nucleotides and proteins, regulating the redox 
status and participating in protein and nucleic acid 
methylation [76, 77]. The conversion of serine to glycine 
can be catalyzed either by the cytosolic or mitochondrial 
serine hydroxymethyltransferase (SHMT1 and SHMT2, 
respectively). Interestingly, the metabolic activity of 
SHMT2 has been shown to strongly correlate with 
the rates of proliferation across the NCI60 cancer cell 
collection [78]. In fact, SHMT2 has been suggested as 
fundamental to sustain cancer metabolism by fuelling 
heme biosynthesis and thus oxidative phosphorylation 
[79].
It is worth noting that the reactions catalyzing the 
degradation of proline produce significant amounts of 
ROS. The first step of proline degradation is catalyzed 
by the mitochondrial proline dehydrogenase (PRODH), 
which is a tumor suppressor that inhibits proliferation and 
induces apoptosis [70, 80]. This mitochondrial enzyme is 
linked to the electron transport chain through complex III, 
being shown as a source of ROS generation. In addition, 
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P5C and proline can act as a redox couple, carrying 
reducing potential into and oxidizing potential out of the 
mitochondria by the combined activities of mitochondrial 
PRODH and the cytosolic form of P5C reductase (PYCR), 
which preferably uses NADPH [70, 80, 81]. 
It is worth noting that glutamine is the amino acid 
presenting the most prominent role in tumor metabolism. 
Accordingly, some tumor cells have been reported to 
exhibit dependence on glutamine for survival [22, 82]. 
Mitochondrial metabolism
Mitochondrial function is essential for cancer cells 
as it is involved in numerous crucial cellular processes 
such as ATP generation, regulation of programmed cell 
death, and regulation of signal transduction pathways 
through ROS production, modulation of cytosolic 
calcium levels and trafficking of small metabolites. 
Indeed, impairment of mitochondrial function and 
reduction of mitochondrial biogenesis greatly suppresses 
tumor formation, growth and proliferation [63, 83, 84]. 
Conversely, enhancement of mitochondrial biogenesis is 
figure 2: Mitochondrial metabolism. Schematic representation of the biosynthetic and bioenergetic reactions of the TCA cycle and 
the oxidative phosphorylation (OXPHOS). OXPHOS is coupled to the oxidation of NADH and FADH
2
, which are produced in the TCA 
cycle, via the electron transport chain (ETC, also known as the mitochondrial respiratory chain). The ETC comprises four complexes (I to 
IV) that transfer electrons generating a gradient of protons (H+) in the mitochondrial intermembrane space, which is used by the ATPase 
(complex V) to produce ATP. Reductive carboxylation of α-ketoglutarate by IDH1 and IDH2 produces citrate (dashed arrows). ACLY, ATP 
citrate lyase; ATP, adenosine triphosphate; CoA, coenzyme A; FADH
2
, flavin adenine dinucleotide reduced form; GAC, glutaminase C; 
GDH, glutamate dehydrogenase; GLS1, glutaminase 1; GOT1, glutamic-oxaloacetic transaminase 1 cytoplasmic form; GOT2, glutamic-
oxaloacetic transaminase 2 mitochondrial form; IDH1, isocitrate dehydrogenase cytoplasmic form; IDH2, isocitrate dehydrogenase 
mitochondrial form; KGA, kidney (K-type) glutaminase; LDH, lactate dehydrogenase; ME1, malic enzyme 1 cytoplasmic form ; NAD+, 
nicotinamide adenine dinucleotide oxidized form; NADH, nicotinamide adenine dinucleotide reduced form; NADP+, nicotinamide adenine 
dinucleotide phosphate oxidized form; NADPH, nicotinamide adenine dinucleotide phosphate reduced form; PC, pyruvate carboxylase; 
PDH, pyruvate dehydrogenase.
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advantageous for tumor cells [63, 85]. On the other hand, 
alterations in mitochondrial function can lead to several 
diseases including cardiovascular dysfunctions, muscular 
degeneration and cancer [83, 86]. 
In the presence of oxygen, oxidative phosphorylation 
(OXPHOS) is the most efficient mechanism for 
synthesizing ATP [29]. OXPHOS is coupled to the 
oxidation of reduced nicotinamide adenine dinucleotide 
(NADH) and flavin adenine dinucleotide (FADH
2
) through 
the electron transport chain. The mitochondrial respiratory 
chain, located in the mitochondrial inner membrane, 
comprises four complexes (I to IV) that are responsible 
for the oxidation of the reducing equivalents in the form 
of NADH or FADH
2
 and the reduction of molecular 
oxygen (final electron acceptor) to water. This process is 
coupled to the pumping of protons into the mitochondrial 
intermembrane space, resulting in a proton gradient that 
is used by the ATPase (complex V) to produce ATP [87] 
(Figure 2).
Among the metabolic pathways that take place 
in the mitochondria, the tricarboxylic acid (TCA) cycle 
is a route of pivotal importance for the entire cellular 
metabolism and, in particular, for oxidative metabolism. 
Remarkably, TCA cycle provides precursors for the 
biosynthesis of lipids, nucleic acids and proteins, as well 
as reducing equivalents (NADH and FADH
2
) for ATP 
production (Figure 2). Mutations in several genes that 
encode enzymes of the TCA cycle including isocitrate 
dehydrogenase [88, 89], succinate dehydrogenase and 
fumarate hydratase [90] are associated with some tumor 
types, leading to the dysfunction of the TCA cycle 
and the accumulation of its substrates [86, 91, 92]. 
Interestingly, it has been shown that increased levels 
of TCA cycle intermediates fumarate and succinate 
can affect α-ketoglutarate-dependent histone and DNA 
demethylases, HIF stabilization, and cellular responses to 
O
2
 depletion [90, 93]. Isocitrate dehydrogenases (IDHs) 
catalyze the oxidative decarboxylation of isocitrate to 
α-ketoglutarate, which is required as a substrate for 
numerous dioxygenases, including histone demethylases, 
prolyl hydroxylases, collagen prolyl-4-hydroxylases, and 
the TET family of 5-methylcytosine hydroxylases [94, 
95]. There are three IDH enzymes; IDH1 is found in the 
cytosol and peroxisome, while IDH2 and IDH3 isoforms 
are localized in the mitochondria. Mutations targeting 
IDH1 and IDH2 result in loss of their native enzymatic 
activities and lead to the production of 2-hydroxyglutarate, 
a metabolite that can competitively inhibit α-ketoglutarate-
dependent dioxygenases and is associated with 
tumorigenesis [95-97]. 
glutamine metabolism
Glutamine is the most abundant amino acid in 
plasma and in intracellular pools, being consumed at 
significantly higher rates than other amino acids by tumor 
cells [82]. Glutamine plays several cellular key roles as 
a nitrogen donor for nucleotide and protein synthesis, 
as a carbon source for energy production and lipid 
biosynthesis, and as a precursor for some non-essential 
amino acids and the antioxidant GSH biosynthesis [82, 
98]. Despite being a non-essential amino acid, glutamine 
is crucial for the proliferation of most cells and for 
the viability of some tumor cells that have developed 
glutamine dependence [99]. 
The expression levels of oncogenes (e.g. MYC [22, 
100], mTOR [101] and KRAS [102]) and tumor suppressors 
(e.g. SIRT4 [103] and TP53 [104]) are decisive to regulate 
glutamine metabolism [92, 105], to the extent that tumor 
genetics can dictate cellular dependence on glutamine for 
survival [98]. For instance, tumor cells overexpressing 
MYC reprogram their mitochondrial metabolism to 
depend on glutamine for the maintenance of cell viability, 
mitochondrial integrity and TCA cycle anaplerosis, 
triggering cellular addiction to glutamine and displaying 
increased sensitivity to glutamine deprivation [22, 100].
In addition to glycolysis, many tumor cells also rely 
on glutamine to fulfill their bioenergetic and metabolic 
needs. Indeed, glutamine catabolism is the source of many 
precursors for major anaplerotic processes such as the 
TCA cycle. Cells requiring de novo lipid biosynthesis, like 
tumor cells, divert citrate from the TCA cycle to produce 
lipogenic acetyl-CoA. The depletion of citrate from the 
TCA cycle creates a need for anaplerotic replenishment 
of the cycle, which can be provided through oxidative 
metabolism of glutamine [106]. Oxidation of glutamine in 
the mitochondria begins with its conversion to glutamate 
catalyzed by glutaminase (GLS). Glutaminase is a pivotal 
enzyme in the regulation of glutamine metabolism in 
tumor cells which has recently gathered some attention 
as a promising target for cancer therapy [107-109]. There 
are three mammalian glutaminase isoforms; kidney 
(K-type) glutaminase (KGA) and glutaminase C (GAC) 
are encoded by GLS and referred to as GLS1, while liver 
(L-type) glutaminase (LGA) is encoded by GLS2 and 
usually known as GLS2 [110]. Glutamate can be converted 
to α-ketoglutarate by either glutamate dehydrogenase 
(GDH) or transaminases, to feed the TCA cycle (Figure 
2). In addition, glutamate can serve as a precursor of GSH 
and non-essential amino acids such as aspartate, alanine, 
proline and arginine. Interestingly, α-ketoglutarate levels 
are determinant for the regulation of HIF1α degradation 
through prolyl hydroxylase (PHD) sensing pathway [67, 
94]. Furthermore, glutaminolysis and α-ketoglutarate are 
also involved in the activation of mTOR signaling [68, 
111]. Glutamine carbons can exit the TCA cycle in the 
form of malate, which can be converted to pyruvate by 
malic enzyme (ME) with NADPH generation [112]. Both 
glutamine-derived NADPH and GSH production allow 
tumor cells to reduce the oxidative stress associated with 
mitochondrial respiration and rapid cell proliferation.
It is worth noting that glutamine utilization as a 
respiratory substrate through the TCA cycle produces 
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NADH and FADH
2
 that provide electrons for the 
mitochondrial electron transport chain to generate ATP 
(Figure 2). Remarkably, glycolytic contribution to total 
ATP synthesis in tumor cells differs widely depending on 
cell type, from over 60% to less than 1%, with a mean 
contribution of 17±18% in the tested cell lines [113]. 
These results are confirmed by a flux balance analysis 
across the NCI-60 cell lines [78, 114] which shows that 
oxidative phosphorylation contributes to 70-84% of the 
total cellular ATP production [115]. Therefore, oxidative 
metabolism of glutamine is the major energetic source in 
many cancer cell lines.
Together, glucose and glutamine are the two 
principal nutrients to coordinately fuel the proliferation 
of tumor cells by supplying not only ATP but also key 
precursors for protein, lipid and nucleic acid biosynthesis 
(Figures 1 and 2). In fact, some cancer cells can switch 
their carbon source in response to nutrient availability. 
For example, glucose withdrawal increases GDH activity 
in MYC-transformed glioblastoma cells [116], while 
impairing the oxidative metabolism of glutamine by 
silencing glutaminase induces a compensatory anaplerotic 
mechanism catalyzed by pyruvate carboxylase (PC) that 
enables the use of glucose-derived pyruvate for anaplerosis 
[117]. However, the metabolic compensation adopted by 
tumor cells renders them absolutely dependent on the 
new upregulated pathways, opening new opportunities 
for cancer combined therapies. Therefore, the metabolic 
flexibility and compensatory abilities exhibited by 
some tumor cells have to be carefully considered when 
designing cancer therapies.
glutamine reductive carboxylation
There are two different glutamine-dependent 
pathways for fatty acid biosynthesis. On the one 
hand, cells can oxidatively metabolize glutamine-
derived α-ketoglutarate to citrate in the TCA cycle 
and subsequently transport it to the cytosol to generate 
oxaloacetate and lipogenic acetyl-CoA [62]. Likewise, 
malate produced from glutamine in the TCA cycle can 
generate pyruvate through the action of malic enzyme, 
which can be further metabolized to lipogenic acetyl-
CoA. On the other hand, α-ketoglutarate obtained 
from glutamine can be directly converted to citrate by 
reductive carboxylation, especially in tumor cells under 
hypoxic conditions or when mitochondrial respiration 
is impaired, in order to sustain cell growth under these 
circumstances [118-121]. This reaction takes advantage of 
the reversible transformation catalyzed by aconitase and 
isocitrate dehydrogenase. The cytosolic NADP+/NADPH-
dependent isocitrate dehydrogenase 1 (IDH1) is the main 
enzyme catalyzing the reversible reductive carboxylation 
of α-ketoglutarate to isocitrate and NADP+ [118] (Figure 
2). Indeed, reductive carboxylation of glutamine provides 
a glucose-independent pathway to generate acetyl-CoA for 
biosynthesis, allowing cells to conserve glucose for the 
production of biosynthetic precursors that are specifically 
generated from glucose [118].
oncogenIc regulAtIon of tuMor 
MetAbolIc reprogrAMMIng
Tumor metabolic reprogramming is a direct result 
of the re-engineering of intracellular signaling pathways 
that are altered by mutations in oncogenes and tumor 
suppressor genes. In fact, most cancers harbor activating 
mutations of oncogenes and/or inactivating mutations 
of tumor suppressor genes which determine the tumor 
metabolic phenotype and support tumorigenesis by giving 
to transformed cells a proliferative advantage over non-
malignant cells. Several oncogenes including MYC, 
hypoxia inducible factor 1 (HIF1), phosphoinositide-3-
kinase (PI3K), protein kinase B (PBK or Akt) and the 
mechanistic target of rapamycin (mTOR), have been 
known to be involved in the regulation of tumor metabolic 
reprogramming [5, 20, 92].
MYc as a master regulator of tumorigenesis
The MYC oncogene belongs to the MYC family of 
genes together with MYCN and MYCL. However, MYC 
is the only isoform ubiquitously expressed in a broad 
range of tissues, while MYCN and MYCL are normally 
only expressed during development [122]. MYC is a 
multi-functional transcription factor that exerts control 
over cell proliferation, cell cycle progression, cell 
growth, metabolism, apoptosis, differentiation and stress 
response through transcriptional regulation of its target 
genes [122, 123]. In fact, MYC binds to the promoter 
of 10-15% of all known genes, regulating both genes 
encoding proteins and those encoding non-coding RNA 
products of several functional classes [122, 124]. MYC 
expression is dysregulated in many human cancers by 
either chromosomal translocation or gene amplification. 
In addition, the expression and stability of MYC protein 
and MYC mRNA can also be dysregulated, promoting 
tumorigenesis through unrestricted cell proliferation, 
inhibition of cell differentiation, metabolic adaptation, 
angiogenesis, reduction of cell adhesion and genomic 
instability [122, 123, 125, 126]. 
To function as a transcription factor, MYC protein 
heterodimerizes with its binding partner MAX, forming 
an activated complex that recognizes E box sequences 
(CACGTG) and induces the transcription of its targets 
genes. MYC can also act as transcriptional repressor 
by binding to MIZ1 or SP1 transcription factors and 
interfering with their transcriptional activity [127]. It is 
worth noting that multiple genes that are repressed by 
MYC encode negative regulators of cell proliferation 
such as CDKN2B (encoding p15INK4b), CDKN2C (p18INK4c), 
CDKN1A (p21Cip1), CDKN1B (p27Kip1), and CDKN1C 
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(p57Kip2) [127]. MAX can also bind to MAD1, MXI1, 
MAD3, MAD4 and MNT or form homodimers, repressing 
the transcriptional activation of MYC target genes [128]. 
MYc and metabolism
MYC is known to enhance glycolysis through the 
activation of glycolytic genes (such as HK2, GAPDH, 
ENO1 and PK, among others) and glucose transporters 
(SLC2A1, SLC2A2 and SLC2A4) [129, 130]. In addition, 
figure 3: Metabolic regulation by MYc. MYC has a pivotal role in the metabolic reprogramming of tumor cells by enhancing 
glucose uptake and glycolysis, lactate production and export, glutamine uptake and glutaminolysis, mitochondrial biogenesis and oxidative 
phosphorylation, and nucleotide, folate, polyamine, proline and serine synthesis. AMD1, adenosylmethionine decarboxylase; ATP, 
adenosine triphosphate; CAD, carbamoyl-phosphate synthase/aspartate carbamoyltransferase/dihydroorotase; CoA, coenzyme A; CTPS1, 
cytidine triphosphate synthase 1; DHFR, dihydrofolate reductase; FADH
2
, flavin adenine dinucleotide reduced form; GAC, glutaminase 
C; GART, phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimida-zole 
synthetase; GDH, glutamate dehydrogenase; GLS1, glutaminase 1; KGA, kidney (K-type) glutaminase; LDHA, lactate dehydrogenase 
A; MCT1, monocarboxylate transporter/SLC16A1 solute carrier family 16 member 1; NAD+, nicotinamide adenine dinucleotide oxidized 
form; NADH, nicotinamide adenine dinucleotide reduced form; NADP+, nicotinamide adenine dinucleotide phosphate oxidized form; 
NADPH, nicotinamide adenine dinucleotide phosphate reduced form; ODC, ornithine decarboxylase; P5CS, Δ1-pyrroline-5-carboxylate 
synthetase; PHGDH, phosphoglycerate dehydrogenase; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; PSPH, phosphoserine 
phosphatase; PYCR1, Δ1-pyrroline-5-carboxylate reductase 1; SHMT1, serine hydroxymethyltransferase 1; SLC1A5, solute carrier family 
1 (neutral amino acid transporter) member 5; SLC2A1, solute carrier family 2 (facilitated glucose transporter) member 1; SLC2A2, solute 
carrier family 2 (facilitated glucose transporter) member 2; SLC2A4, solute carrier family 2 (facilitated glucose transporter) member 4; 
SLC7A5, solute carrier family 7 (amino acid transporter light chain, L system) member 5; SLC19A1, solute carrier family 19 (folate 
transporter) member 1; SRM, spermidine synthase.
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MYC promotes lactate production and export, increasing 
the gene expression of LDHA and lactate transporter 
MCT1 [126, 131, 132]. Figure 3 illustrates the main 
metabolic pathways regulated by MYC.
On the other hand, transformed cells exhibit 
increased MYC-dependent glutaminolysis and glutamine 
dependency [22, 73]. Indeed, MYC has been described 
as the main oncoprotein responsible for inducing a 
transcriptional program that promotes glutaminolysis and 
triggers cellular addiction to glutamine as a bioenergetic 
substrate [22]. This glutamine addiction leads tumor 
cells to reprogram intermediate metabolism for the 
maintenance of mitochondrial tricarboxylic acid (TCA) 
cycle integrity [22]. Moreover, high levels of MYC 
promote mitochondrial biogenesis and function, both 
increasing the rate of oxygen consumption and the energy 
production required for rapid cell proliferation [125, 
133-135]. High glutaminolysis rate results in the robust 
production of NADPH, which is needed to fulfill the 
requirements for cell proliferation [22, 112]. In conditions 
of low glucose and oxygen availability, MYC-induced 
glutamine catabolism is important for cell survival [108]. 
Furthermore, cells with supraphysiological levels of MYC 
are more sensitive to inhibition of mitochondrial oxidative 
metabolism [136]. Moreover, MYC is also found to 
contribute to increase glutamine uptake by upregulation 
of the expression of glutamine transporters (ASCT2 
[SLC1A5] and SLC7A5) [73, 85]. Importantly, MYC 
enhances glutaminolysis by transcriptionally repressing 
miR-23a and miR-23b (microRNA-23a/b), resulting in 
greater expression of their target protein, glutaminase 
(GLS1) [73]. In fact, GLS1 is the first enzyme in the 
glutaminolysis and catalyzes the conversion of glutamine 
to glutamate for its oxidation in the TCA cycle and also 
for protein or glutathione synthesis. It is worth mentioning 
that MYC can stimulate the use of the TCA cycle to 
generate intermediates for macromolecular synthesis 
using both glucose and glutamine as carbon source [98, 
108]. However, it has been reported that cells presenting 
high MYC levels greatly rely on mitochondrial oxidative 
phosphorylation and increase glutaminolysis by 2- to 
4-fold, while only moderately increasing glycolysis by 
1.2-fold [137].
Additionally, MYC has been shown to activate 
nucleotide biosynthesis by inducing several gens 
involved in nucleotide metabolism including carbamoyl-
phosphate synthase / aspartate carbamoyltransferase 
/ dihydroorotase (CAD), CTP synthase 1 (CTPS) and 
ornithine decarboxylase (ODC) [129, 132, 138, 139]. 
Polyamine biosynthesis is also regulated by MYC since 
ornithine decarboxylase (ODC) (the rate-limiting enzyme 
in polyamine production) [138], adenosylmethionine 
decarboxylase (AMD1) and spermidine synthase (SRM) 
have E boxes in their regulatory region and are enhanced 
in MYC-expressing cells [132]. Furthermore, polyamines 
stimulate MYC transcription in a positive feedback loop 
[140, 141]. 
Moreover, MYC can redirect glycolytic flux from 
3-phosphoglycerate for the synthesis of serine and glycine 
involving folate metabolism, which are essential for 
purine and thymidylate biosynthesis [85, 132, 142, 143]. 
MYC is also implicated in proline metabolism regulation 
by transcriptionally repressing proline oxidase/proline 
dehydrogenase (POX/PRODH) expression through 
upregulation of miR-23b*, and increasing the expression 
of the enzymes of proline biosynthesis pathway (P5C 
synthase, P5CS and P5C reductase 1, PYCR1) [70].
MYc and cell cycle
The network of MYC target genes suggests 
its implication in the fulfillment of the metabolic 
requirements for cell cycle entry [136, 144]. In fact, one 
of the earliest observations after MYC discovery was 
its ability to promote cell proliferation and inhibit cell 
differentiation [129]. Remarkably, MYC overexpression 
in quiescent cells is sufficient to trigger cell cycle entry, 
reduce the requirement for growth factors, block cell cycle 
exit, and increase cell size [145, 146]. MYC promotes 
cell cycle progression by regulation of pivotal cell cycle 
control genes through transcriptional induction of CDKs 
and cyclins, and repression of CIP/KIP proteins. MYC 
mediates the increase of active cyclin-CDK complexes 
levels not only by upregulation of CDK1, CDK2, CDK4 
(one of the principal MYC target genes [147]), CDK6, 
CCND1 (encoding cyclin D1), CCND2 (cyclin D2), 
CCND3 (cyclin D3), CCNE1 (cyclin E1), CCNE2 (cyclin 
E2), CCNA2 (cyclin A2) and CCNB1 (cyclin B1), but 
also by induction of CDC25A (CDKs phosphatase) and 
CDK activating kinase complex (CAK, through enhanced 
mRNA translation of its subunits, CDK7, cyclin H and 
MAT1), and repression of the CDK inhibitory kinase 
WEE1 through miR-221 activation [122, 126, 129, 145, 
148]. Moreover, MYC abrogates the transcription of cell 
cycle checkpoint genes GADD45 and GADD153 [122, 
148], and impairs the activity of the CDK inhibitors 
p27Kip1, p21Cip1 and p15INK4b through several mechanisms 
[122, 126, 129, 145]. One of the most studied mechanisms 
for p21Cip1 and p15INK4b MYC-mediated repression is the 
binding to MIZ1 and the blocking of its transcriptional 
activity [129, 145]. In contrast, MYC antagonizes p27Kip1 
function by several parallel mechanisms such as induction 
of miR-221 and miR-222, activation of E2F transcription 
factors, increase of CDK4/6-cyclin D and CDK2-cyclin E 
complexes levels, and enhancement of the expression of 
several components of the SCF ubiquitin ligase complex 
[122, 145]. Last but not least, MYC further stimulates cell 
cycle progression by inducing genes directly involved 
in DNA replication including MCM (minichromosome 
maintenance), ORC (origin recognition complex), 
CDC6 (cell division cycle 6), TERT (telomerase reverse 
transcriptase) and the genes encoding three subunits of the 
APC/C (ANAPC5, CDC16 and CDC23) [145].
Oncotarget62736www.impactjournals.com/oncotarget
MYc regulation
Given its pivotal role on cell fate, MYC expression 
is tightly regulated at transcriptional, post-transcriptional 
and post-translational levels in non-transformed cells. 
Accordingly, dysregulation of MYC expression is one 
of the most common abnormalities in human diseases, 
being MYC overexpression frequently found in most 
human cancers. Remarkably, MYC oncogenic activation 
results from insertional mutagenesis, chromosomal 
translocation and gene amplification mechanisms, while 
most oncogenes are activated by mutations in their coding 
sequence [122]. 
MYC protein presents extremely short half-life 
(in the order of 20-30 minutes [149]) in the absence of 
mitogenic signals, but is transiently stabilized upon cell 
cycle entry and RAS activation, allowing its accumulation 
[150, 151]. RAS promotes MYC stability through RAF/
MEK/ERK kinase cascade and via glycogen synthase 
kinase-3β (GSK-3β) inhibition by the PI3K/Akt pathway 
[150, 152]. MYC turnover is regulated by the ubiquitin 
proteasome pathway [149, 153] and is dependent on 
the phosphorylation of two highly conserved residues 
located near the N-terminal region of MYC, Thr58 and 
Ser62. These phosphorylation sites exert opposing 
control effects on MYC degradation [150]. ERK 
(extracellular receptor kinase) phosphorylates MYC 
on Ser62, promoting its protein accumulation, while 
phosphorylation of Thr58, which is mediated by GSK-3β 
but dependent on prior Ser62 phosphorylation, triggers 
MYC proteasomal degradation [150-152, 154]. Therefore, 
MYC phosphorylation at Ser62 has two opposite roles; 
MYC stabilization and accumulation, and activation 
of the subsequent phosphorylation at Thr 58, triggering 
MYC degradation. Interestingly, proteasome inhibition 
studies reveal that the accumulated poly-ubiquitinated 
MYC only exhibits phosphorylation on Thr58 [152, 154]. 
Since phosphorylation on Ser62 is required prior to Thr58 
phosphorylation, the Ser62 phosphate is removed before 
MYC ubiquitination by protein phosphatase 2A (PP2A) 
action, contributing to MYC degradation [150, 152, 154]. 
In non-transformed cells, growth stimuli lead to 
RAS activation and MYC protein synthesis. However, 
when mitogenic signaling ends, RAS and PI3K activities 
decline and release GSK-3β from its negative regulation, 
activating its kinase activity and thus promoting MYC 
degradation by phosphorylation on Thr58 [154]. The 
ordered phosphorylation of Ser62 and Thr58 followed by 
Ser62 dephosphorylation allows a tight control of MYC 
protein levels. Hence, the disruption of the physiological 
regulation of MYC expression can lead to malignancy. 
HIf1
The hypoxia inducible factors HIF1, HIF2 and 
HIF3 are the principal regulators of the transcriptional 
homeostatic responses to situations of limited availability 
of oxygen. HIF1 is ubiquitously expressed while HIF2 
and HIF3 are only expressed in certain tissues [155]. Only 
HIF1 and HIF2 are further discussed in this section since 
HIF3 function is less well understood. The HIF factors 
Figure 4: HIF1α regulation under normoxia. In the presence of oxygen and α-ketoglutarate, HIF1α subunits are hydroxylated on 
proline residues in the oxygen-dependent degradation (ODD) domain by prolyl hydroxylases (principally prolyl hydroxylase 2, PHD2). 
Prolyl hydroxylation is required for the binding of the von Hippel-Lindau protein (VHL), which recruits an ubiquitin ligase complex 
(E3) that ubiquitinates HIF1α. Ubiquitination marks HIF1α for proteasomal-mediated degradation. HIF, hypoxia inducible factor; OH, 
hydroxylation; Ub, ubiquitin.
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are composed of an oxygen-dependent HIFα subunit and 
a constitutively expressed HIFβ subunit. HIF activity 
is tightly regulated by cycles of synthesis and oxygen-
dependent proteasomal degradation. Indeed, HIFα 
subunits are continuously synthesized and their stability is 
regulated by oxygen availability [155]. Under normoxic 
conditions, HIFα subunits are hydroxylated on proline 
residues in the oxygen-dependent degradation (ODD) 
domain by prolyl hydroxylase enzymes (PHDs) and 
subsequently ubiquitinated by the tumor suppressor protein 
von Hippel-Lindau (VHL) prior to their degradation in 
the proteasome [155, 156] (Figure 4). Under hypoxic 
conditions, the reduced molecular oxygen levels decrease 
the activity of PHDs, which are further inactivated through 
the oxidation of the ferrous ion within their active sites by 
ROS released from inefficient mitochondrial respiration 
[157], thus preventing their interaction with VHL [156]. 
Consequently, stable HIFα subunits form heterodimers 
with HIFβ subunits and translocate to the nucleus, where 
they bind to specific consensus sequences (hypoxia 
response element, HRE) in the promoter of hypoxia-
responsive genes for the transcriptional activation of the 
cellular adaptation to hypoxia [158].
Hypoxia and cancer
Solid tumors frequently develop hypoxia when 
highly proliferating tumor cells outgrow their vascular 
network, resulting in tumors with limited oxygen diffusion. 
In order to adapt to the hypoxic microenvironment 
and support cell survival, cells principally initiate 
response mechanisms through HIFα stabilization and 
accumulation, favoring angiogenesis, invasion and 
metabolic reprogramming [159, 160]. Accordingly, HIFα 
levels are increased in many human cancers and correlate 
with poor clinical prognosis [160]. It is worth mentioning 
that tumor cells can exhibit augmented levels of HIF1α 
under normoxic conditions, a phenomenon known as 
pseudo-hypoxia [159]. For example, induction of RAS 
or SRC oncogenic signaling promotes normoxic HIF1α 
accumulation through prolyl hydroxylation inhibition 
[161].
regulation of HIf by prolyl hydroxylases
In humans, there are three different members of 
the prolyl hydroxylase family; PHD1, PHD2 and PHD3. 
However, only PHD2 has been confirmed to be involved 
in the oxygen regulation of HIF1α, while PHD1 and PHD3 
display only partial additive effects on HIF1α stability 
[162]. These enzymes are good oxygen sensors since 
their affinity for oxygen is low with Km values from 230 
to 250 µM, slightly above the concentration of oxygen 
in the air (200 µM) [163]. PHDs require α-ketoglutarate, 
oxygen and a prolyl residue as substrates, and iron and 
ascorbate as cofactors, to produce a hydroxyl-prolyl 
residue, succinate and CO
2
 [94]. Prolyl hydroxylation is 
required for the recognition and binding of VHL to the 
ODD domain, which recruits an ubiquitin ligase complex 
[158] (Figure 4). Chemical inhibitors of the activity 
of PHD, such as iron chelators (e.g. desferrioxamine, 
DFO) or competitors of α-ketoglutarate for binding at 
the hydroxylase (e.g. dimethyloxalylglycine, DMOG), 
prevent the hydroxylation of HIFα subunits, causing their 
accumulation and promoting the expression of HIF target 
genes [164]. Remarkably, the use of α-ketoglutarate as 
an electron donor in the reaction of hydroxylation results 
in its oxidation into succinate, which is an end product 
whose accumulation can inhibit PHD activity even in the 
presence of oxygen [93]. In fact, deficiency of succinate 
dehydrogenase has been demonstrated to increase 
succinate levels and competitively inhibit PHDs under 
normoxia, leading to HIF1α stabilization in a pseudo-
hypoxic phenotype [93]. Interestingly, PHD activity can be 
rescued by artificially increasing cellular α-ketoglutarate 
levels both in normoxia, reversing the succinate-mediated 
HIF1α stabilization [165], and hypoxia, resulting in 
the destabilization of HIF1α and reversing the hypoxic 
phenotype [166]. Therefore, PHD activity is regulated not 
only by oxygen availability, but also by the availability 
of α-ketoglutarate, a metabolite which plays a central 
role in numerous metabolic processes and is closely 
connected to amino acid metabolism [94]. In fact, both 
intracellular α-ketoglutarate levels and PHD activity are 
highly dependent on amino acid availability, while amino 
acids ability to induce mTORC1 signaling requires PHD 
enzymatic activity [167]. 
It is worth noting that, in addition to the principal 
mechanism regulating HIF1α stability in response to 
oxygen availability involving PHD and VHL, there 
are also oxygen-independent pathways regulating the 
synthesis and degradation of HIF1α, which involve 
RACK1 (receptor for activated C kinase 1) protein binding 
to HIF1α, recruitment of an ubiquitin ligase complex and 
consequent HIF1α proteasome-mediated degradation [158, 
168].
HIf transcriptional targets
HIF1α and HIF2α overlap in their ability to activate 
target genes involved in angiogenesis, metastasis and 
invasion, while HIF1α alone regulates several glycolytic 
and apoptotic genes and HIF2α preferentially promotes the 
transcription of certain genes such as vascular endothelial 
growth factor (VEGF) or transforming growth factor α 
(TGFα) [155, 159, 164, 169]. 
HIF1 activation increases oxygen and nutrients 
supply to tumors through angiogenesis and erythropoiesis 
stimulation by VEGF and erythropoietin (EPO) 
upregulation, respectively [21]. In addition, as part of 
the molecular mechanisms associated with the Warburg 
effect, HIF1 enhances glycolysis and lactate production 
by transactivating glucose transporters and glycolytic 
enzymes [170]. In accordance with the increased aerobic 
glycolysis, HIF1 prevents the mitochondrial oxidation of 
pyruvate, the final product of glycolysis, by inhibiting 
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the activity of pyruvate dehydrogenase (PDH) through 
pyruvate dehydrogenase kinase 1 (PDHK1) induction 
[171]. Furthermore, HIF1 enhances electron transport 
chain efficiency through cytochrome c oxidase subunit 
IV, isoform 2 (COX4I2) induction, which replaces the less 
efficient isoform 1 (COX4I1), resulting in increased ATP 
production and reduced ROS generation [172]. In addition 
to the catabolic process of anaerobic glycolysis, HIF1 also 
endorses anabolic processes such as glycogen synthesis 
by upregulating the enzymes involved in its biosynthetic 
pathway [173-175].
HIf1 effects on MYc
There is a complex interplay between HIF1 and 
MYC proteins concerning glucose metabolism and 
mitochondrial function [131, 156, 176]. Both HIF1 and 
MYC share common metabolic target genes such as 
SLC2A1 glucose transporter, HK, phosphofructokinase 
(PFK), pyruvate kinase (PK) or LDH, among others [131]. 
In contrast, SLC2A3 glucose transporter is a specific HIF1 
target gene [131]. On the other hand, HIF1 and MYC 
have opposing effects on cell proliferation, mitochondrial 
biogenesis and DNA repair [176]. HIF1 impairs 
mitochondrial biogenesis and oxygen consumption by 
inhibiting MYC-mediated transcription and inducing 
MYC degradation [134], while regulates cell cycle and 
DNA repair genes by functionally counteracting MYC 
through displacement of MYC inhibitory binding from the 
CDKN1A promoter [177] and of MYC activating binding 
from MSH2 and MSH6 promoters [178]. Remarkably, 
HIF1 directly inhibits MYC through induction of MXI1, 
which binds to MAX and represses MYC transcriptional 
activity, and through promotion of MYC proteasomal 
degradation [134, 179]. Indeed, HIF increases MYC 
phosphorylation at Thr58, triggering MYC ubiquitination, 
and decreases the de-ubiquitinating enzyme USP28, 
promoting MYC proteasome-dependent degradation 
[180]. On the other hand, MYC induces MCM3 and 
MCM5 proteins [145] which in turn inhibit HIF1 activity 
by stimulating HIF1α hydroxylation, ubiquitination and 
degradation [181, 182]. However, prolonged hypoxic 
conditions reduced MCM mRNA expression in a HIF1-
dependent manner, indicating that MCM and HIF1 display 
antagonistic functions [181, 182]. Interestingly, HIF1 
and MYC present sirtuin-mediated shared regulation 
mechanisms since sirtuin 1 (SIRT1) works in conjunction 
with both transcription factors while SIRT6 inhibit 
their transcriptional activity via effects on chromatin 
[183]. Moreover, dual deficiency of oxygen and glucose 
suppresses HIF signaling [184] and enhances MYC 
degradation in cancer cells as an adaptive response to 
survive under conditions of deficient energy sources [185]. 
the pI3K/Akt pathway
Overactivation of phosphoinositide-3-kinase 
(PI3K)/Akt signaling is commonly observed in human 
cancers, as it is essential for cell proliferation, growth, 
survival and metabolic reprogramming [186]. PI3Ks are 
a family of lipid kinases that integrate prosurvival signals 
such as growth factors, cytokines, hormones and other 
environmental cues, translating them into intracellular 
signals that activate Akt-dependent and Akt-independent 
downstream signaling pathways [186]. Akt is a serine-
threonine protein kinase that is mainly regulated following 
PI3K activation and through sequential phosphorylation 
at Thr308 and Ser473 [187, 188]. Since constitutive 
activation of Akt is frequently found in human tumors, 
being a central node in the PI3K/Akt signaling pathway, it 
is potentially interesting to molecularly target components 
of this pathway for cancer therapy [188]. 
Forkhead box O (FOXO) transcription factors are 
direct targets of Akt that modulate cell cycle, growth, 
DNA repair, survival, apoptosis, metabolism, cellular 
differentiation, resistance to oxidative stress and tumor 
suppressor pathways [189-193]. Four different FOXO 
proteins are encoded in mammalian cells; FOXO1, 
FOXO3a and FOXO4, which are ubiquitously expressed, 
and FOXO6, which is expressed predominantly in 
neural cells [194, 195]. Post-translational modifications 
such as phosphorylation, acetylation and ubiquitination 
regulate the translocation of FOXO proteins to the 
nucleus [196] where they activate transcription by 
binding to gene regulatory regions [197]. The principal 
mechanism of FOXO transcriptional regulation is FOXO 
phosphorylation by Akt which impairs its DNA binding 
activity and promotes its interaction with the chaperone 
protein 14-3-3. This interaction triggers the nuclear 
exclusion, cytoplasmic accumulation and ubiquitin-
proteasome pathway-dependent degradation of FOXO 
factors, and promotes cell survival [198, 199]. In the 
presence of oxidative stress, FOXO proteins are activated 
and released from 14-3-3 through Jun N-terminal kinase 
(JNK) signaling [189, 191, 200, 201] (Figure 5). 
FOXM1 transcription factor is a crucial regulator 
of cell proliferation and cell cycle progression that 
is overexpressed in many types of cancer. Cell 
differentiation, angiogenesis, senescence, DNA damage 
repair and tissue homeostasis are regulated by FOXM1, 
conferring oncogene-like properties to this forkhead 
subfamily member [202]. Recent studies have reported 
that FOXO3a represses FOXM1 expression and that they 
both compete for binding to similar DNA sequences, 
sharing numerous target genes but being antagonists [196, 
203-205]. It is worth noting that FOXO3a and FOXM1 
proteins are indirect targets of several conventional and 
widely used cytotoxic chemotherapeutic drugs such as 
cisplatin or gefitinib, which mediate their effects through 
FOXO3a activation and FOXM1 indirect repression via 
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PI3K/Akt signaling pathway inhibition [206-211]. The 
dysregulation of the PI3K/Akt/FOXO3a axis may lead 
to drug resistance by enhancing DNA repair, as well 
as cancer cell maintenance, proliferation and survival 
through overexpression of FOXM1 [196, 202].
A hallmark of most cancers where the PI3K/Akt 
pathway is hyperactivated is the inactivation of FOXO 
proteins [188, 201], postulating FOXO family members 
as tumor suppressors [212]. Accordingly, PI3K depletion 
results in FOXO proteins activation, induction of 
apoptosis, decrease of cell viability and G1 cell cycle arrest 
with inhibition of CDK4/6, cyclin D and accumulation of 
p27Kip1 [213]. Indeed, in vivo models of loss of FOXO 
function exhibit spontaneous tumor formation, while 
FOXO overexpression can inhibit tumorigenesis [191, 
211, 212, 214-216]. Even though FOXO transcription 
factors are considered to be tumor suppressors, genetic 
inactivation of FOXO is not often found in human cancers, 
being predominantly repressed through overactivation of 
the PI3K/Akt pathway caused by mutations in RAS, PTEN 
or PI3K genes [212]. Therefore, the search for compounds 
that promote activation and relocalisation of FOXO from 
the cytoplasm to the nucleus is a promising therapeutic 
approach for cancer treatment and overcoming drug 
resistance [215, 217].
FOXO effects on MYC, HIF1α and mTOR
Activated PI3K/Akt pathway stimulates cell growth 
and proliferation, and stabilizes MYC through inhibition 
of GSK3β by preventing MYC phosphorylation at Thr58 
[154]. Active PI3K and MYC specifically cooperate 
in dysregulation of cell growth and proliferation, since 
both regulate a common set of cellular processes [218]. 
Conversely, activation of FOXO transcription factors 
following inhibition of PI3K/Akt signaling represses 
multiple MYC target genes including those involved in 
cell proliferation and mitochondrial activity, blocking 
MYC-mediated cell proliferation and transformation, 
and reducing ROS production [219, 220]. In addition, 
FOXO3a induces the expression of the MAD/MXD 
family of transcriptional repressors, although MXI1 is 
the only member that is its direct target. Indeed, MXI1 is 
necessary for efficient inhibition of MYC transcriptional 
activity [221]. Furthermore, FOXO3a activation 
considerably reduces MYC protein levels by enhancing 
phosphorylation of MYC at Thr58, which triggers its 
proteasomal degradation [220]. Interestingly, FOXO3a-
mediated regulation of MYC at different levels enables 
both acute inhibition of mitochondrial gene expression 
by MYC degradation and sustained inhibition through 
MXI1 antagonistic effects [222]. Therefore, the inhibition 
of the transcriptional activity of FOXO proteins by Akt-
mediated phosphorylation is required for MYC-induced 
cell proliferation and transformation [219].
FOXO3a is induced under hypoxic conditions 
as a direct target gene of HIF1 to mediate the hypoxic 
repression of nuclear-encoded genes with mitochondrial 
function by directly antagonizing MYC at their 
promoters, resulting in reduced mitochondrial mass, 
oxygen consumption and ROS production [223, 224]. 
Additionally, FOXO3a promotes cell survival both in 
hypoxic tumor cells and hypoxic tumor tissue in vivo, 
in contrast with its role as a tumor suppressor under 
normoxic conditions [212, 223]. On the other hand, 
FOXO3a prevents HIF1α stabilization by blocking the 
hypoxia-induced ROS increase [220], and inhibits HIF1α 
figure 5: foXo regulation by growth factors and oxidative stress. Growth factors activate PI3K/Akt pathway, resulting in 
FOXO factors phosphorylation, impairment of FOXO binding activity to DNA and promotion of FOXO interaction with the chaperone 
protein 14-3-3, which in turn causes FOXO nuclear exclusion, cytoplasmic accumulation and ubiquitin-proteasome pathway-dependent 
degradation. Oxidative stress activates Jun N-terminal kinase (JNK) signaling, which phosphorylates both FOXO (at other regulatory sites 
than Akt) and 14-3-3 proteins, triggering the release of FOXO factors, their nuclear translocation and their transcriptional activity. Akt/
PBK, protein kinase B; FOXO, forkhead box O; P, phosphate; PI3K, phosphoinositide-3-kinase.
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activity through stimulation of CITED2 (Cbp/p300-
interacting transactivator 2) expression, also reducing 
HIF1α-induced apoptosis during hypoxic stress and 
promoting cell survival [224].
In response to energy stress, FOXO proteins inhibit 
the mechanistic target of rapamycin complex 1 (mTORC1) 
signaling through induction of BCL2/adenovirus E1B 
19kDa interacting protein 3 (BNIP3) expression, which 
in turn negatively regulates the mTORC1 activator RHEB 
and the BCL2 pro-survival family members, resulting 
in energy stress-induced apoptosis [225]. In addition, 
mTORC1 inhibition upregulates FOXO3a expression and 
nuclear accumulation through FOXO3a demethylation 
[226]. Conversely, mTOR complex 2 (mTORC2) 
phosphorylates the Class IIa histone deacetylases 
(HDACs) in an Akt-independent manner, resulting in 
FOXO acetylation, release of MYC proteins from FOXO-
mediated repression and the consequent conferral of 
resistance to PI3K and Akt Inhibitors [227]. 
mtor
The mechanistic target of rapamycin (mTOR, 
formerly mammalian TOR) is a conserved cytoplasmic 
serine-threonine protein kinase that acts as a central cell 
growth regulator by sensing mitogens, energy and amino 
acids. mTOR pathway regulates cell survival and growth 
through modulation of some pivotal cellular processes 
including protein synthesis, ribosome biogenesis, 
autophagy and metabolism [228]. In fact, the dysregulation 
of mTOR-dependent cellular homeostasis maintenance is 
associated with several human diseases such as cancer and 
figure 6: effects of pI3K and mtor on central carbon metabolism. PI3K and mTOR signaling pathways positively regulate 
each other’s activity, as well as glucose uptake and glycolysis, oxidative metabolism and glutaminolysis. mTOR also promotes fatty 
acids synthesis and cell survival and growth. ACLY, ATP citrate lyase; ATP, adenosine triphosphate; CoA, coenzyme A; FADH
2
, flavin 
adenine dinucleotide reduced form; GAC, glutaminase C; GDH, glutamate dehydrogenase; GLS1, glutaminase 1; GOT1, glutamic-
oxaloacetic transaminase 1 cytoplasmic form; GOT2, glutamic-oxaloacetic transaminase 2 mitochondrial form; IDH1, isocitrate 
dehydrogenase cytoplasmic form; IDH2, isocitrate dehydrogenase mitochondrial form; KGA, kidney (K-type) glutaminase; LDH, lactate 
dehydrogenase; ME1, malic enzyme 1 cytoplasmic form; NAD+, nicotinamide adenine dinucleotide oxidized form; NADH, nicotinamide 
adenine dinucleotide reduced form; NADP+, nicotinamide adenine dinucleotide phosphate oxidized form; NADPH, nicotinamide adenine 
dinucleotide phosphate reduced form; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase.
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considerable research efforts have been made to efficiently 
inhibit mTOR signaling [229, 230].
mTOR forms two functionally and structurally 
different multiprotein complexes named mTOR complex 
1 (mTORC1) and 2 (mTORC2). mTORC1 activity 
is regulated by growth factors, oxygen and nutrient 
availability. Activation of PI3K/Akt and RAS/RAF/
ERK pathways by growth factors results in Akt- and 
ERK-mediated phosphorylation and inactivation of the 
heterodimer tuberous sclerosis 1 (TSC1)/TSC2, which is a 
GTPase-activating protein (GAP) that negatively regulates 
mTORC1 through inhibition of the RAS homolog enriched 
in brain (RHEB) GTPase [231]. Remarkably, intracellular 
amino acids are necessary for the activation of mTORC1 
since they activate the mechanism by which mTORC1 is 
able to interact with and be activated by RHEB [67]. 
Activated mTORC1 signaling cascade initiates 
with the direct phosphorylation of the regulators of 
translation eukaryotic translation initiation factor 4E 
(eIF4E)-binding protein 1 (4E-BP1) and S6 kinase 1 
(S6K1), which promote protein synthesis [232]. In 
addition, mTORC1 regulates lipid homeostasis through 
activation of the transcription factors sterol regulatory 
element-binding protein 1/2 (SREBP1/2), which in turn 
control the expression of genes involved in fatty acid, 
triglyceride, phospholipid and cholesterol synthesis [228, 
233]. Interestingly, mTORC1 also promotes mitochondrial 
biogenesis and the expression of genes involved in 
oxidative metabolism [234, 235]. On the other hand, 
mTORC2 pathway regulation and function remain poorly 
understood. mTORC2 signaling is independent of nutrient 
availability but is sensitive to PI3K signaling [228]. 
mTORC2 directly activates Akt through phosphorylation 
of the Ser473 residue, which in turn activates mTORC1, 
both situating mTOR upstream and downstream of Akt 
[236]. It is worth noting that acute rapamycin treatment 
specifically inhibits mTOR when it is part of mTORC1 but 
not of mTORC2 [228, 229].
mtor regulation by hypoxia and MYc
Hypoxic oxygen levels inhibit mTORC1 by 
activating the TSC1/TSC2 complex through two different 
pathways. On the one hand, hypoxia reduces cellular 
ATP levels and triggers 5’-AMP-activated protein kinase 
(AMPK) activation, which positively regulates TSC1/
TSC2 in a HIF1-independent manner [237]. On the other 
hand, hypoxia activates TSC1/TSC2 by the transcriptional 
induction of regulated in development and DNA damage 
responses 1 (REDD1) gene, antagonizing other pathways 
that promote growth through TSC1/TSC2 inhibition via 
Akt [238, 239]. Hypoxia can also negatively regulate 
mTORC1 through the hypoxia-inducible protein BNIP3 
binding to RHEB, which inhibits the ability of RHEB 
to activate mTORC1 [240]. Conversely, MYC acts 
as a strong and direct repressor for TSC2 expression 
by binding to its promoter, resulting in mTORC1 
activation [241]. In addition, mTORC1 downstream 
effector S6K1 phosphorylates the eukaryotic initiation 
factor eIF4B, enhancing MYC translation efficiency 
and positively regulating glutaminase (GLS) and 
glutamate dehydrogenase (GDH) [101, 242]. Moreover, 
glutaminolysis and α-ketoglutarate production, in response 
to glutamine and leucine [68], also mediate mTORC1 
activation [111].
In summary, mTOR, PI3K, HIF and MYC are key 
regulators of cellular metabolism that are frequently 
altered in cancer, collaborating in both synergistic 
and antagonistic ways. A better understanding of the 
relationship between these pathways as well as the 
identification of other key players in the regulation of 
the tumor metabolic reprogramming are fundamental 
challenges for the development of new strategies for 
cancer treatment.
tHerApeutIc perspectIves
targeting metabolic reprogramming in cancer 
therapy
Development of malignancy is accompanied by 
a complete metabolic reprogramming closely related 
to the acquisition of most of cancer hallmarks [2, 28]. 
Many known genetic and epigenetic alterations converge 
in a common adaptation of tumor cell metabolism 
[30]. Indeed, metabolic properties of tumor cells are 
significantly different from those of non-transformed 
cells. In addition, tumor metabolic reprogramming is 
linked to drug resistance in cancer treatment [243, 244]. 
Accordingly, metabolic adaptations are also involved in 
different therapeutic approaches for cancer therapy. It is 
worth noting that some of the first chemotherapeutical 
agents used in cancer treatment were antimetabolites, 
such as aminopterin, methotrexate or 5-fluorouracil, that 
impaired the nucleotide synthesis and DNA replication 
[245, 246]. From then on, numerous metabolic pathways 
and enzymes have been successfully tested as anticancer 
targets [247]. Since aerobic glycolysis is one of the 
key metabolic features of cancer cells, many studies 
are focused on inhibiting this pathway by blocking the 
enzymes that control it [248]. Targeting the PPP with 
dehydroepiandrosterone (DHEA) and oxythiamine to 
respectively inhibit G6PD and TKT has also proven 
to have antitumor effects [50, 244, 249]. Interestingly, 
promoting pyruvate dehydrogenase (PDH) activity with 
dichloroacetate (DCA) presents promising results with 
minor side effects in early phase clinical trials with 
glioblastoma patients by suppressing angiogenesis, 
increasing mitochondrial ROS, inducing apoptosis, 
blocking HIF1 signaling and activating tumor suppressor 
p53 [250-252]. In fact, DCA inhibits PDHK leading 
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to the metabolic switch from glycolysis to oxidative 
phosphorylation through PDH reactivation [250]. 
Moreover, combined therapies with DCA and conventional 
cancer therapeutics such as omeprazole and tamoxifen 
show synergistic antitumor effects which can overcome 
drug resistance [253]. Ongoing clinical trials with DCA as 
a single agent or in combination with other therapeutics are 
being conducted for patients with recurrent or metastatic 
solid tumors and head and neck carcinoma (clinical trials 
NCT00566410 and NCT01386632).
There is a growing interest on the development of 
pharmacological strategies to inhibit tumor glutamine 
metabolism. The use of amino acid analogues such as 
acivicin led to severe side effects in clinical trials, aiming 
for more selective therapeutic strategies [254]. As a 
result, GLS1 isoform has emerged as a promising target 
for cancer therapy and several specific small molecule 
inhibitors of GLS1 have recently been characterized. 
Compound 968 and BPTES (bis-2-(5-phenylacetamido-
1,2,4-thiadiazol-2-yl)ethyl sulfide) are two allosteric 
inhibitors of GLS1 that exhibit antitumor activities in 
numerous pre-clinical studies and several tumor types 
[100, 108, 121, 255-257]. Remarkably, the selective 
inhibitor of GLS1 known as CB-839 presents in vitro 
antiproliferative activity against acute myeloid leukemia 
cells [258], and a panel of triple-negative breast cancer cell 
lines, but not estrogen receptor (ER) or human epidermal 
growth factor receptor 2 (HER2) positive cell lines, as 
well as in vivo efficacy in breast cancer xenograft models 
[107]. In addition, CB-839 has recently entered phase I 
clinical trials without displaying central nervous system 
toxicity (clinical trials NCT02071862 and NCT02071888). 
In fact, GLS1 inhibition is a good strategy for tumor 
cells that overexpress MYC and thus present glutamine 
dependence [22, 99]. It is worth mentioning that, to date, 
no effective MYC inhibitors have been developed despite 
the fact that MYC overexpression is frequently found in 
human cancers [125, 259-261]. However, targeting GLS1 
significantly antagonizes the growth of tumors presenting 
MYC overexpression and can be exploited as a novel 
antitumor therapy [100]. 
combination therapies
The identification of cytotoxic compounds has 
led the development of antitumor therapeutics until in 
the recent years chemotherapy advanced into the era of 
molecularly targeted therapeutics [262]. The bases of 
molecular targeted cancer therapy are to selectively kill 
tumor cells while sparing non-malignant cells, and prevent 
tumor resistance emergence and relapse [263]. However, 
solid tumors response to targeted monotherapy is limited 
and frequently associated with the development of drug 
resistance. In addition, the design of targeted therapies 
requires the definition of the activated oncogenic pathways 
in transformed cells and the availability of selective 
small-molecule inhibitors directed to these pathways. The 
modest efficacy of current therapies is also caused by the 
high degree of tumor clonal and genetic heterogeneity, 
since inhibition of a single target does not necessarily 
eradicate the tumor. Therefore, the use of combination 
therapies of selective agents and/or cytotoxic agents that 
inhibit two or more molecular targets in a single pathway, 
or in parallel or compensatory pathways, is an attractive 
strategy for cancer treatment [264]. Additionally, the 
simultaneous inhibition of multiple targets or redundant 
pathways is aimed at improving treatment efficacy and 
overcoming and/or preventing the emergence of adaptive 
resistance.
Then, in order to select appropriate molecular 
targets for inhibition or modification, is necessary to 
first perform a tumor expression profiling to identify its 
specific oncogenic signatures, and confirm that the target 
is tumor specific, non-redundant, and able to influence 
the outcome of tumor progression [263, 265]. However, 
many oncogenic pathways cannot be directly targeted 
with small-molecule inhibitors [260]. Remarkably, gene 
expression analysis can be used as a predictive tool to 
identify the oncogenic pathways which are dysregulated in 
a specific tumor, providing a potential basis for guiding the 
use of pathway-specific drugs and directing combination 
therapies aimed to slow tumor growth and progression, 
improve treatment response, and overcome therapeutic 
resistance [265].
concludIng reMArKs
The understanding of cancer cell biology is of 
pivotal importance to identify biomarkers for early 
diagnosis and design new therapeutic strategies. In 
particular, tumor cells switch their core metabolism 
to meet the increased requirements of cell growth and 
division. Accordingly, oncogenic signals converge to 
reprogram tumor metabolism by enhancing key metabolic 
pathways such as glycolysis, PPP, glutaminolysis and 
amino acid, lipid and nucleic acid metabolism [19, 63]. 
Therefore, tumor metabolic reprogramming is a direct 
result of the re-engineering of intracellular signaling 
pathways that are altered by activating mutations in 
oncogenes, loss-of-function mutations in tumor suppressor 
genes and epigenetic modifications, which finally gives 
to transformed cells a proliferative advantage over non-
malignant cells [5, 6]. However, the final tumor phenotype 
depends on the homeostatic nature of metabolism, since 
metabolic rewiring is associated with compensatory 
and regulatory adjustments. There are several levels of 
metabolic adaptations, from changes in the concentrations 
and fluxes associated with substrate-enzyme affinities 
to adjustments coordinated by metabolite-based 
regulatory loops or determined by changes in the activity 
of regulatory proteins (e.g. MYC and HIF). In fact, 
metabolic rewiring allows tumor cells to exhibit rapidly 
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adaptive responses to changes in tumor microenvironment, 
promoting tumor progression and acquired resistance to 
targeted therapeutics [266, 267]. On the other hand, tumor 
metabolic adaptation after single-agent treatment can 
reveal new cell dependences and vulnerabilities which, 
in turn, may be potential candidates to be targeted in 
combination therapies. The final aim of the combination 
treatments is to achieve synergistic therapeutic effect, 
dose and toxicity reduction, and to minimize or delay the 
induction of drug resistance [268].
Personalized medicine in cancer requires the correct 
diagnosis of cancer to give patients the most appropriate 
treatment according to their individual circumstances and 
the molecular characteristics of their tumors. However, 
personalized medicine is still at a relatively early stage 
in its development, and therefore the classification of 
cancers is based on critical molecular targets identified by 
translational research. Hence, more efforts should be put 
into understanding the tumor biology in order to identify 
the involved targets and determine the optimum treatment 
for each specific tumor. Likewise, the developing of 
new therapeutic strategies that specifically target the 
molecular pathways involved in promoting tumor cell 
proliferation and survival, such as targeted therapies, is 
a major focus of cancer research today [263]. However, 
the currently available chemotherapeutic treatments 
exhibit modest efficacy due to their side effects and 
drug resistance [267]. In addition, the design of more 
efficient targeted therapies requires a better definition of 
the activated oncogenic pathways in transformed cells 
and the availability of selective small-molecule inhibitors 
directed to these pathways. In this context, the search for 
combined chemotherapies with low systemic toxicity that 
inhibit two or more molecular targets in a single pathway, 
or in redundant or compensatory pathways, is a promising 
strategy for cancer treatment [264]. With this purpose, 
both metabolic tumor characterization and gene expression 
analysis can be used to identify the dysregulated molecular 
pathways in a specific tumor, providing a potential basis 
for guiding the use of target-specific drugs and directing 
combination therapies [265].
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